GU MED Onc @sloan_kettering, focused in #kidneycancer, @BIDMC_IM alum, views=own
Manhattan, NY
Joined February 2020
- Tweets21
- Following235
- Followers215
- Likes19
Ritesh Kotecha retweeted
Moving the needle in #kidneycancer science is fundamental to the KCA's mission.
We are grateful to our generous community who make it possible to fund investigators and make a difference for patients & families!
🧡 Stay involved & help support research kidneycancer.org/ways-to-giv…
Ritesh Kotecha retweeted
We are pleased to announce Dr. @KotechaMD as a speaker at VIRO 2026 – Global Voices in Renal Oncology.
Dr. Kotecha is Assistant Attending Physician in the Genitourinary Oncology and Cellular Therapy Service at @MSKCancerCenter, United States. His clinical and research interests focus on biomarkers, immunotherapy, and novel cellular therapy approaches for renal cell carcinoma.
His expertise in kidney cancer, immunotherapy, and innovative cellular therapies will bring valuable perspective to this international discussion on contemporary kidney cancer management.
🔗 Register here: oncodaily.com/viro-registrat…
Additional faculty announcements will follow soon.
Ritesh Kotecha retweeted
Though CAR T cells have been effective against certain blood cancers, they have not been for solid tumors.
Now, a new form of highly sensitive CAR T cells aims to overcome one of the biggest barriers in solid tumor immunotherapies—the way solid tumors lack a single, widely shared surface target.
By engineering an ultra-sensitive receptor capable of detecting even the smallest amounts of the protein CD70, researchers report in Science they were able to eradicate kidney, ovarian, and pancreatic tumors in preclinical models.
The findings provide a potential strategy to treat a broad range of solid tumors. scim.ag/400e2WU
Ritesh Kotecha retweeted
🧵 How do older patients actually do with dual IO for mccRCC?
Presenting at #ASCOGU2026 a joint @MSKCancerCenter + @MDAndersonNews collaboration–the largest reported real-world cohort of patients treated with 1L ipilimumab/nivolumab (>500 pts).
Here's what we learned ⬇️
Ritesh Kotecha retweeted
On behalf of a terrific team of investigators (@BGarmezy @KotechaMD @DrKarieRuncie @BraunMDPhD et al), very proud to present the 1st data for XmAb819, a first-in-class ENPP3 x CD3 bispecific in patients with #kidneycancer. We have long needed new targets beyond #VEGF-axis & checkpoint inhibition. If you are at the @AACR @theNCI @EORTC #Targets25, come visit our poster in the session starting at noon today - if not, read below ... (1/8)
Ritesh Kotecha retweeted
🔍 2pm at #KCRS25: Trials in Progress led by @motzermd - packed w updates you won’t want to miss:
@NazliDizman IVORY
@KotechaMD ENPP3 x CD3
@BradMcG04 STRIKE
@PrafulRavi1 LASER
@DrKarieRuncie EXACT
@VincentWenxinXu NK cell immune therapy
Plenty to discuss!
Ritesh Kotecha retweeted
New research from @MSKCancerCenter takes a step toward off-the-shelf CAR T cell therapy for #cancer. Author Karlo Perica explains his and Michel Sadelain's recent study in @Nature that demonstrated cells from healthy donors can be stored for future use. bit.ly/40W306e
Ritesh Kotecha retweeted
Our paper on IO combinations in metastatic translocation RCC is now online. Great collaborative work and addition to treatment outcomes in this rare entity. journals.lww.com/immunothera… @nirmishsingla @montypal @KotechaMD @MattZibelman
Ritesh Kotecha retweeted
Gene expression of prostate-specific membrane antigen (FOLH1) in clear cell renal cell carcinoma predicts angiogenesis and response to tyrosine kinase inhibitors buff.ly/3UON4PS
Ritesh Kotecha retweeted
A new article from our group with @KotechaMD and led by Lennert Eismann + Amy Xie reports that investigational RNA biomarkers in RCC (and likely other diseases) are sensitive to tissue source site (i.e. whether they are obtained from primary or met tissue) sciencedirect.com/science/ar…
Ritesh Kotecha retweeted
📣Dr. Rupesh Kotecha, chief of radiosurgery, has been invited to present with the Middle Eastern Society for Stereotactic and Functional Neurosurgery at their first-ever Stereotactic Radiosurgery Webinar.
@RrKotecha will be discussing the current state of modern #SRS platforms. Congratulations Dr. Kotecha!
Learn more: forms.gle/cNdsg95CjJn3m4NT6
Ritesh Kotecha retweeted
Thank you @KidneyCancer for this tremendous & humbling opportunity to help advance the field of research for patients affected by kidney cancer! Incredibly grateful for support of my mentors & collaborators at @WilmotCancer & @MSKCancerCenter that made the proposal possible @ChungHanLee3 @KotechaMD @IyerGopa Dr Van Veldhuizen
We are✨THRILLED✨ to announce the 2023 KCA grant recipients! These six talented researchers will address critical #kidneycancer issues through their work and help move the needle for pts & families. More about each in a🧵. Congrats! #UnstoppableTogether kidneycancer.org/2023-grant-…
Ritesh Kotecha retweeted
(1/n) Our latest work in @EurUrolFocus bit.ly/3YxpWnL is a retrospective study from @MSKCancerCenter and @MDAndersonNews reporting outcomes with ICT by CN status in patients with sarcomatoid and/or rhabdoid dediff @PavlosMsaouel @arihakimi @KotechaMD
Ritesh Kotecha retweeted
Genetic ancestry and molecular correlations in patients with #KidneyCancer. Presentation by @KotechaMD @MSKCancerCenter. #IKCSNA22 written coverage by @MikeLattanzi @TexasOncology > bit.ly/3h3y53l @KidneyCancer
Ritesh Kotecha retweeted
Progression-free Survival After Second Line of Therapy for Metastatic Clear Cell Renal Cell Carcinoma in Patients Treated with First-line Immunotherapy Combinations
buff.ly/3Uf2NoX
@ChungHanLee3 @KotechaMD @Dr_Aggen @DrNeilJShah @DrDarrenFeldman @motzermd
Ritesh Kotecha retweeted
Last #KCRS22 tweet: @KotechaMD and I went to @MidlandPS ‘s Dow High years ago. Now, as a GU #geneticcounselor and #oncologist , conference run ins have become a norm. Mr. Koski (our AP Bio teacher) would be so proud. #michiganstrong
Ritesh Kotecha retweeted
New work on SDH-/FH-deficient RCC from our @MSKCancerCenter Kidney Cancer Team, driven by (newly matched!) med student Angela Yoo, Cerise Tang, and Mark Zucker. Thanks @arihakimi @KotechaMD, all collaborators, and of course the patients who contributed sciencedirect.com/science/ar…
Ritesh Kotecha retweeted
We are part of this outstanding Academy of Kidney Cancer Investigators @BraunMDPhD @AChakrabortyPhD @KotechaMD Amrita Mangalvedhekar and Krishnendu Pal. Thank you for your leadership and guidance @brian_rini
